Aptose Presents Early Phase 1a/b CG-806 Clinical Findings at the 25th Congress of the European Hematology Association
12 juin 2020 07h00 HE
|
Aptose Biosciences, Inc.
Safety, tolerability and phospho-BTK inhibition at first three CG-806 dose levels in patients with CLL and other B-cell malignancies Plasma from CG-806 treated patients completely inhibited...
Aptose to Present Early CG-806 Clinical Findings at the 25th Congress of the European Hematology Association
14 mai 2020 09h00 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, May 14, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated...
Aptose Presents New Preclinical CG-806 Data at the 2019 ASH Annual Meeting
09 déc. 2019 11h00 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Dec. 09, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting...
Aptose Doses First CLL Patient in Phase 1 Study of CG-806 and Doses Third Cohort in Phase 1 Study of APTO-253
16 juil. 2019 07h05 HE
|
Aptose Biosciences, Inc.
– CG-806 oral non-covalent pan-FLT3/pan-BTK inhibitor being developed for the treatment of CLL and other B-cell malignancies and for AML – – APTO-253 MYC inhibitor being developed for the...
Aptose Presents New Preclinical Data for CG-806 at the 24th Congress of the European Hematology Association
14 juin 2019 07h00 HE
|
Aptose Biosciences, Inc.
– CG-806 safely and durably suppressed tumor growth in preclinical models – SAN DIEGO and TORONTO, June 14, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ:...
Aptose Announces FDA Allowance of Investigational New Drug Application for CG-806
25 mars 2019 07h02 HE
|
Aptose Biosciences, Inc.
– CG-806 highly potent, oral, non-covalent pan-FLT3/pan-BTK inhibitor being developed for the treatment of CLL and other B-cell malignancies and for AML – – Phase 1 trial in relapsed or refractory...
Aptose to Present New CG-806 and APTO-253 Data at the 2019 AACR Annual Meeting
28 févr. 2019 07h00 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated...
Aptose Biosciences Submits IND Application for CG-806
25 févr. 2019 07h00 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), today announced that it has submitted an Investigational New...